News
Videos
Conferences
Events
Resources
Subscribe

|Videos|September 22, 2017

Making Treatment Decisions When Cancer Recurs

Newsletter

Stay up to date on cancer updates, research and education

Related Content

The FDA has granted approval to treatment with Rubraca for some adult patients with previously-treated metastatic castration-resistant prostate cancer: © stock.adobe.com.

FDA Grants Regular Approval to Rubraca for Some With Prostate Cancer

December 17th 2025

Newly diagnosed with stage 3 prostate adenocarcinoma? Understand your diagnosis, explore multimodality treatment options, potential side effects, and key questions to ask your oncologist for an informed cancer journey.

Stage 3 Prostate Cancer: A Guide to Diagnosis, Treatment, and Next Steps

December 14th 2025

The FDA approved Akeega combination therapy for adults with BRCA2-mutated metastatic castration-sensitive prostate cancer.

FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer

BySpencer Feldman

December 12th 2025

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer.

Breaking Down the Prostate Cancer Treatment Renaissance

December 9th 2025

Image of bladder.

Pedmark Reduces Chemo-Induced Hearing Loss in Children With Cancer

December 2nd 2025

Trending on CURE

Reading the Fine Print: Why Ingredient Awareness Matters After Cancer

Gedatolisib Plus Faslodex Shows Efficacy in Advanced HR+ Breast Cancer

Stigmas Faced by Patients With Lung Cancer

Addressing Concerns on Diet During Breast Cancer Treatment

Early Data Show INCA033989 Activity in Calreticulin-Driven Myelofibrosis